Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|170|5|669-678

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.170, Iss.5, 2015-09, pp. : 669-678

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 401-407

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B‐cell malignancies

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 175, Iss. 1, 2016-10 ,pp. : 55-65

John Wiley & Sons Inc

Access to resources Recommend Favorite

The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 701-710

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 4, 2015-05 ,pp. : 528-533

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 4, 2015-11 ,pp. : 463-470

John Wiley & Sons Inc

Access to resources Recommend Favorite